Tax expenses hurt Lupin's profit in FY12, but sales up 22% on growth in core markets

 
• By Anju Ghangurde
  
Generate a summary of this article
Listen to this article
Beta

Lupin has reported a 22% increase in net sales to Rs69.59 billion ($1.29 billion) for the year ended March 2012 backed by strong growth across its key geographies of the US, Japan and India, but tax expenses took the sheen off profits during the year. Net profits increased marginally to Rs8.67 billion as compared with Rs8.62 billion, largely due to a 168.3% increase in tax outflows to Rs3.08 billion on account of an increase in effective tax rates and tax on inventories shipped to overseas subsidiaries for new launches. Profits in the last quarter declined by 31% to Rs1.56 billion on account of tax expenses.

Lupin has reported a 22% increase in net sales to Rs69.59 billion ($1.29 billion) for the year ended March 2012 backed by strong growth across its key geographies of the US, Japan and India, but tax expenses took the sheen off profits during the year. Net profits increased marginally to Rs8.67 billion as compared with Rs8.62 billion, largely due to a 168.3% increase in tax outflows to Rs3.08 billion on account of an increase in effective tax rates and tax on inventories shipped to overseas subsidiaries for new launches. Profits in the last quarter declined by 31% to Rs1.56 billion on account of tax expenses.

Formulation sales in the US, Europe and Japan increased by 25% to Rs35.88 billion and these markets contributed 52% of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Alimentary/Metabolic

More from Therapeutic Category